Takeda Touts Trinity Of Rusfertide, Oveporexton, Zasocitinib In Growth Strategy

 
• By Alaric DeArment
  
Takeda's booth at the 2025 American Society of Hematology meeting in Orlando, Fla. (Alaric DeArment)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business